PharmaCord LLC, a prominent provider of patient services and commercialization solutions for life sciences companies, has announced the completion of an investment by funds advised by Permira, a global investment firm. This investment aims to accelerate PharmaCord's technology roadmap and expand its service lines. Founder and CEO Nitin Sahney, along with the management team, will continue to lead the company and remain significant investors alongside Permira.

Nitin Sahney expressed enthusiasm about the partnership, highlighting its potential to enhance client experiences through new technology and service expansions. He emphasized the shared objectives with Permira and the opportunity to accelerate PharmaCord's growth trajectory.

Permira, known for its extensive experience in the pharma and pharma services sector, is well-positioned to support PharmaCord's next growth phase. The investment will enable PharmaCord to focus on strategic ambitions, including business expansion and technology transformation.

Jon Maschmeyer, Partner at Permira, expressed excitement about the deal's closure and the opportunity to work with PharmaCord's team. He noted the rising demand for specialty pharmaceuticals and complex therapeutic treatments, underscoring the importance of PharmaCord's offerings. Maschmeyer emphasized Permira's commitment to supporting PharmaCord's growth and enhancing patient outcomes.

Financial advisors for the transaction included Centerview Partners for PharmaCord and Jefferies LLC and Leerink Partners for Permira. Legal counsel was provided by Willkie Farr & Gallagher for PharmaCord and Skadden, Arps, Slate, Meagher & Flom LLP for Permira.

PharmaCord simplifies the patient therapeutic journey for drug manufacturers through its proprietary PharmaCord Lynk™ technology suite, talented team members, and non-commercial pharmacy PharmaCord Scripts™. The company aims to improve commercial outcomes for life sciences companies.

Permira, founded in 1985, advises funds across private equity and credit, with approximately €80bn in committed capital. The firm invests in technology, consumer, healthcare, and services sectors. Permira has a strong track record in healthcare, having partnered with 19 companies in specialty pharma, medical devices, and tech-enabled healthcare services.

For more information about PharmaCord and Permira, visit their respective websites.